Phase II Neoadjuvant Study of Capivasertib Plus Fulvestrant Versus Fulvestrant Alone in Primary High-risk Lobular Breast Cancer
Led by GBG Forschungs GmbH · Updated on 2025-04-02
120
Participants Needed
25
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effect of adding capivasertib to fulvestrant compared with fulvestrant alone as neoadjuvant treatment for women with primary high-risk lobular breast cancer that is hormone receptor positive and HER2 negative. This phase II, open-label, randomized study focuses on measuring the complete cell cycle arrest CCCA by assessing Ki67 levels at baseline, week 2, and week 10. The study aims to identify patients who may benefit from combined treatment and potentially avoid chemotherapy, considering the unique characteristics of invasive lobular breast cancer.
Participants are randomly assigned to one of two treatment groups. One group receives capivasertib orally twice daily for 4 days followed by a 3-day break for 2 weeks, then continues this capivasertib schedule combined with fulvestrant injections every 28 days for an additional 8 weeks, totaling four doses of fulvestrant. The other group receives fulvestrant injections alone on the same schedule for 10 weeks. Treatment continues until surgery, disease progression, unacceptable side effects, or patient withdrawal.
During the study, all patients will undergo core biopsies before and after treatment to measure Ki67 levels. Researchers will assess safety, pathological response, breast conservation rates, and survival outcomes. Patients will be monitored throughout treatment and follow-up, which may last up to two years to assess invasive disease-free survival and overall survival. Additional therapies such as surgery, chemotherapy, or radiotherapy will be given as needed outside the trial according to standard care.
CONDITIONS
Brief Title
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
Research Team
C
Christina Müller-Weisbrod
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Signed informed consent and willingness to follow the study procedures
Postmenopausal women aged 18 years or older
Unilateral or bilateral untreated primary lobular invasive breast cancer confirmed centrally
Willing and able to provide archived tissue from core biopsy before treatment
HER2-negative and hormone receptor positive disease confirmed on biopsy with Ki67 above 10%
High-risk invasive lobular breast cancer defined by tumor size and nodal involvement
No evidence of distant metastases (no stage IV disease)
ECOG performance status 0 or 1
Estimated life expectancy of at least 5 years
Accessible for visits, treatment, and follow-up
Normal cardiac function per local guidelines
Laboratory values within specified limits for blood counts, liver, kidney, and glucose metabolism
Completed standard staging work-up before starting treatment
You will not qualify if you...
Female patients of childbearing potential
Prior excisional biopsy or lumpectomy before study entry
Surgical axillary staging before randomization except biopsy of lymph nodes
Previous treatment for current breast cancer including hormone, chemo, radiation, or targeted therapy
Use of herbal or natural cancer treatments concurrently
Known allergy to study drugs
Use of strong CYP3A4 inhibitors or inducers within 2-3 weeks before treatment
Gastrointestinal conditions affecting drug absorption
Contraindications to fulvestrant
Evidence of metastatic (stage IV) breast cancer
History of malignancy in last 5 years except certain skin cancers and cervical carcinoma in situ
Insulin-dependent diabetes mellitus
Severe co-morbidities including recent stroke, active infections, or significant cardiac disease
History of HIV, tuberculosis, or hepatitis B
Abnormal heart rhythm or conditions increasing risk of QT prolongation
Recent live vaccinations within 30 days
Major surgery or trauma within 4 weeks before treatment
Participation in other interventional clinical trials within 4 weeks prior to treatment start or concurrent enrollment except non-interventional studies
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to 10 weeks
Participants receive neoadjuvant treatment with either capivasertib plus fulvestrant or fulvestrant alone to assess treatment efficacy.
4 visits for fulvestrant injections plus additional visits for capivasertib dosing
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.